Filing Flows › Pacira BioSciences (PCRX) › Net income
Pacira BioSciences (PCRX) net income by quarter
Pacira BioSciences' net income was $28.5M in Q3 2026 (third quarter 2026), +513% from Q2 2026. Over the last 6 quarters it ranged from $1.6M (Q4 2025) to $28.5M (Q3 2026).
| Quarter | Net income | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $28.5M | +513% | +425% |
| Q2 2026 | $4.7M | +60% | — |
| Q1 2026 | $2.9M | +78% | -39% |
| Q4 2025 | $1.6M | -70% | — |
| Q3 2025 | $5.4M | +13% | — |
| Q1 2025 | $4.8M | — | — |
Q3 2026 at a glance
Pacira BioSciences, Q3 2026: revenue $177M (-2% year over year), operating margin 12.6%, net earnings $28.5M, operating cash flow $50.1M. The chart follows the revenue to costs, profit and cash.
Questions
What is Pacira BioSciences' net income?
Pacira BioSciences' net income was $28.5M in Q3 2026 (third quarter 2026), +513% from Q2 2026.
How has Pacira BioSciences' net income changed?
Over the last 6 quarters it ranged from $1.6M (Q4 2025) to $28.5M (Q3 2026).